Immunoregulatory extracellular vesicles in multiple myeloma patients’ peripheral blood
Extracellular Vesicles and Circulating Nucleic Acids · 06.07.2026 · 7 (3) · 1029-42
DOI: 10.20517/evcna.2025.180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Extracellular Vesicles and Circulating Nucleic Acids, online erschienen am 06.07.2026. Verfasst von Irma Airoldi und 7 weiteren Autor:innen. Beteiligte Einrichtung: UOSD Laboratory of Cell Therapies, IRCCS Istituto Giannina Gaslini, Genova 16147, Italy. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Extracellular vesicles (EVs) mediate cell-to-cell communication and co-contribute in cancer progression and modulation of immune responses. The aim of this work was to characterize the phenotype and function of EVs isolated from the peripheral blood (PB) of multiple myeloma (MM) patients, with particular attention to adenosinergic ectoenzymes.
Methods
EVs were isolated by centrifugation of PB plasma samples from newly diagnosed (ND) MM patients and healthy donors (HD). EVs were characterized by nanoparticle tracking analysis (NTA). Flow cytometry was used to assess the expression of CD138 (a tumor-associated antigen), nicotinamide phosphoribosyltransferase/pre-B cell colony enhancing factor (NAMPT/PBEF1), and adenosinergic ectoenzymes CD38, CD39, CD203a, and CD73. Functional studies were performed by assessing T-cell proliferation in vitro using carboxyfluorescein succinimidyl ester (CFSE) dilution and flow cytometry, with or without EVs to the culture.
Results
The PB EVs size was comparable between MM patients and HDs, whereas EV concentration was significantly higher in MM patients. EVs from MM patients expressed higher levels of CD138, PBEF, CD38, and CD73 than those from HDs. In addition, CD138+ EVs from MM patients expressed higher levels of PBEF, CD38, CD39, and CD73 than CD138- counterparts. Finally, MM-derived EVs inhibited T-cell proliferation in vitro. This inhibition correlated with the expression of CD138 and CD203a.
Conclusion
This study provides the first phenotypic and functional characterization of EVs obtained from the PB of MM patients. The presence of functional adenosinergic molecules may represent a novel immune-escape mechanism operating at distant sites. Nonetheless, further studies are required to define specific contributions of adenosinergic ectoenzymes and other immune-regulatory mechanisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UOSD Laboratory of Cell Therapies, IRCCS Istituto Giannina Gaslini, Genova 16147, Italy.
- These authors contributed equally to this work as first authors.
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genova 16132, Italy.
- IRCCS Ospedale Policlinico San Martino, Genova 16132, Italy.
- Lab of Immunogenetics, Department of Medical Sciences, University of Torino, Torino 10126, Italy.
- Fondazione Ricerca Molinette ETS, Torino 10126, Italy.
Zitieren
APA
Airoldi, I., Soncini, D., Marimpietri, D., Malavasi, F., Horenstein, A. L., Garibotto, M., Cea, M., & Morandi, F. (2026). Immunoregulatory extracellular vesicles in multiple myeloma patients’ peripheral blood. Extracellular Vesicles and Circulating Nucleic Acids, 7(3), 1029-42. https://doi.org/10.20517/evcna.2025.180
Vancouver
Airoldi I, Soncini D, Marimpietri D, Malavasi F, Horenstein AL, Garibotto M, et al. Immunoregulatory extracellular vesicles in multiple myeloma patients’ peripheral blood. Extracellular Vesicles and Circulating Nucleic Acids. 2026;7(3):1029-42. doi:10.20517/evcna.2025.180
BibTeX
@article{Airoldi2026,
author = {Airoldi, Irma and Soncini, Debora and Marimpietri, Danilo and Malavasi, Fabio and Horenstein, Alberto L and Garibotto, Matteo and Cea, Michele and Morandi, Fabio},
title = {Immunoregulatory extracellular vesicles in multiple myeloma patients’ peripheral blood},
journal = {Extracellular Vesicles and Circulating Nucleic Acids},
year = {2026},
volume = {7},
number = {3},
pages = {1029--42},
doi = {10.20517/evcna.2025.180}
}
EUVIMED